Factors Fueling Patients' Mistrust
A growing mistrust of medical providers could be traced back to doubts about scientific validity and treatment costs, according to Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company.
Americans’ trust in physicians and hospitals plummeted 31% after the COVID-19 pandemic, falling from 71.5% in April 2020 to 40.1% in January 2024, according to a study published in JAMA Network Open in August 2024.
Luke Hansen, M.D., M.H.S.
“Erosion of trust in the industry overall, specifically in the providers, is really dangerous,” Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, said in a video interview with Managed Healthcare Executive. “In some ways, I think it’s a response to the larger questioning of scientific validity that's occurring. People might also have financial stress because of their healthcare condition that translates to their provider.”
Hansen went on to explain how patients’ distrust can lead to treatment challenges.
“Fundamental to chronic disease management is behavior change,” he said. “If a patient who has no symptoms of their chronic disease is going to do the right thing, they need to trust whoever is telling them to do the right thing,” he said. “That’s something biological that we're fighting against in human nature.”
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
